Memantine and its therapeutic potential in degenerative CNS disorders;Memantin a jeho terapeutický potenciál u degenerativních poruch CNS

Psychiatrie

Volumn 6, Issue 1, 2002, Pages 35-40

  Patočka, Jiří ^a  

^a J E PURKINJE UNIVERSITY   (Czech Republic)

Author keywords

Dementia; Memantine; Neurodegenerative brain disorders; Neuroprotection; NMDA receptor

Indexed keywords

EXCITATORY AMINO ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG METABOLISM; HUMAN; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NEUROTRANSMISSION; PARKINSON DISEASE; REVIEW;

EID: 0036222279     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor
2. Anticonvulsant effects of memantine and MK-801 in guinea pig hippocampal slices
3. Memantine is a potent blocker of NMDA receptor channels
4. Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug
5. Effects of memantine on synaptic transmission in the hippocampus in vitro
6. Efficacy and tolerability of memantine in patients with dementia syndrome
7. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: A double-blind, placebo-controlled study
8. Effects of intravenous administration of memantine in parkinsonian patients
9. Memantine in the treatment of senile dementia of the Alzheimer type
10. Influence of urine pH and urinary flow on the renal excretion of memantine
11. Treatment of dementia with memantine
12. Memantine in the treatment of mild to moderate dementia syndrome
13. Memantine prevents progressive functional neurodegeneration in rats
14. The use of NMDA-receptor antagonists in the treatment of chronic pain
15. Evidence for alcohol anti-craving properties of memantine
16. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity
17. Memantine prevents quinolinic acid-induced hippocampal damage
18. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
19. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
20. Memantine prevents HIV coat protein-induced neuronal injury in vitro
21. High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats
22. Alzheimer's congress. Drug shows promise for advanced disease
23. Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane. Pharmacological studies in rodents and baboon, Papio papio
24. gp120 of HW-1 induces apoptosis in rat cortical cell cultures: Prevention by memantine
25. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells
26. Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study
27. Clinical and behavioural evaluation in long/term care patients with mild to moderate dementia under memantine treatment
28. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
29. Memantine treatment in alcohol dementia: Rapid PET changes and clinical course
30. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
31. Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial
32. Memantine (1-amino-3,5-dimethyl-adamantane) blocks the serotonin-induced depolarization response in a neuronal cell line
33. Efficacy and tolerability of memantine in patients with dementia
34. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine
35. Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia
36. Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study
37. Glutamate receptor agonists and alcohol dependence. Preclinical findings
38. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat
39. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat
40. No interaction of memantine with acvetylcholinesterase inhibitors approved for clinical use
41. Distribution of memantine in brain, liver, and blood of the rat
42. Gaschromatographic and mass spectrometric studies on metabolites of adamantane amines excreted with urine
43. On the pharmacodynamics and pharmacokinetics of memantine
44. Distribution of metabolism of the potential anti-parkinson drug memantine in the human
45. Memantine in severe dementia: Results of the M-best-study (Benefit and efficacy in severely demented patients during treatment with memantine)
46. Potentiation of the locomotor activity of memantine by aminophylline